CHDI-390576 is employed to investigate its efficacy as an HDAC inhibitor in pre-clinical models of neurodegenerative diseases such as Huntington's disease.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.